Adlai Nortye Ltd.
ANLHealthcare|Biotechnology|SG
$10.28
+0.60 (+6.20%)
DCF Value
$0.48
Tangible Book / Share
$13.49
Cash / Share
$14.56
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07252479 Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations | Solid Tumors (Phase 1), RAS Mutation | P1 | Recruiting | 118 | Open-label | AN9025 oral capsule |
| NCT07686445 A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression | Solid Tumor (Phase I), RAS Mutation | P1 | Recruiting | 228 | Open-label | Intravenous AN4035, Intravenous AN4035 followed by intravenous EGFR Inhibitor. |
| NCT07639047 An Initial Evaluation of AN8025 in Solid Tumors | Advanced Solid Tumor (Phase 1) | P1 | Recruiting | 91 | Open-label | AN8025 is a multifunctional antibody fusion protein |
| NCT04999384 First in Human, Dose Escalation Study of AN4005 | Advanced Solid Tumor, Advanced Lymphoma | P1 | Recruiting | 31 | RCT, Double-blind | AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect |
| NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | Head and Neck Cancer | P3 | Completed | 487 | RCT, Open-label | Buparlisib & Paclitaxel |
| NCT03152370 Preoperative Radiotherapy and E7046 in Rectum Cancer | Neoadjuvant Therapy in Rectal Cancer | P1 | Completed | 29 | Open-label | E7046, capecitabine, folinic acid/5-FU/oxaliplatin (mFOLFOX-6) |
| NCT05519059 Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer | Advanced or Metastatic Breast Cancer | P1 | Completed | 15 | Open-label | Pelareorep |
| NCT05191667 AN0025 and Chemoradiotherapy Combination in Esophageal Cancer | Esophageal Cancer | P1 | SUSPENDED | 32 | Open-label | AN0025 |
| NCT05358691 A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants | Lung Cancer Stage III | P1 | Withdrawn | — | Open-label | AN0025 |
| NCT04975958 Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors | Locally Advanced Solid Tumor | P1 | Completed | 47 | Open-label | AN2025, AN0025, Atezolizumab 1200 mg in 20 ML Injection |
| NCT04432857 AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous | P1 | Unknown | 63 | Open-label | AN0025, Pembrolizumab |